The main efficacy study of the bivalent vaccine was conducted in young women aged 15 through 25 years. Among women who had not been previously exposed to a targeted HPV type, the clinical trials demonstrated 93% vaccine efficacy in preventing cervical precancers due to HPV 16 or 18. In all studies of the bivalent HPV vaccine, more than 99% of females developed an HPV 16 and 18 antibody response 1 month after completing the 3-dose series.

CDC, HPV Vaccine Information for Clinicians - Fact Sheet, 2012

효과 매우 높습니다. 글쓴 분 조금만 더 알아보고 쓰시지 그러셨어요.

부작용이 이슈가 되고 있다고 해서 찾아보니

For the quadrivalent vaccine, detailed safety data reviewed by the US Food and Drug Administration are included in the label and are available at http://www.gardasil.com/. Injection site pain, erythema and oedema were common and occurred significantly more often for vaccine recipients than placebo recipients. Few subjects (0.1%) discontinued due to adverse experiences. Overall, there were no differences in the proportion of women developing a serious adverse event in the vaccine or placebo group. A detailed post-licensure plan is in place to obtain additional safety data.

WHO, Human papillomavirus and HPV vaccines: a review, Bulletin of the World Health Organization, Volume 85, 2007

백신이 주는 이득에 비해서 한없이 낮은 수준이네요. 아 물론 누룩에 알레르기 있으신 분들은 가다실 말고 서바릭스 맞으셔야 됩니다.